StemCell Therapy

Thelma before Stem Cell Therapy
From:krazykp12Views:2 0ratingsTime:01:33More inPeople Blogs

See the original post here:
Thelma before Stem Cell Therapy - Video

SHIMMIAN MANILA - Celebs share good effects of stem cell therapy
From:myrenovatiosolutionsViews:1 0ratingsTime:01:30More inEntertainment

Go here to see the original:
SHIMMIAN MANILA - Celebs share good effects of stem cell therapy - Video

I'm pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today. 


The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration.  The group's focus is on the activities of companies in and serving the space.


The group began in July 2008. It took 2.5 years to reach the first 1000 members, 9 mos to reach 2,0000, 6 months to reach 3,000, and 6 months to meet today's 4,000 member mark. 


As is typical, there is a very high percentage of passive participants but the group benefits from an avid group of participants who post, share, exchange, and debate on a range of topics ranging from regulatory, clinical, commercial, scientific, manufacturing, financial, and other topics of interest to the group.


As the group has grown I've noted two trends pertaining to the composition of the membership:  (a) having tapped out the c-level suite, growth is increasingly coming from down the hierarchy of the corporate food chain and including those in the operational trenches, and (b) a much higher ratio of new members of late is from outside the US, presumably as LinkedIn increasingly penetrates OUS markets.


We strive hard to maintain the quality of the participation by screening each applicant, deleting off-topic posts, moving promotional posts to the "promotions" tab" and encouraging a balance of news-sharing with useful discussion threads.


I'm proud to say the group has become a vibrant and valuable part of the sector due to the hard work and contributions of all involved.    


As these kind of virtual networks become exponentially larger and provide different value than the professional societies representing the sector, I will be fascinated to watch if and how this affects how sectors like our interact and how this will impact the traditional value proposition of member-based professional societies.


If you are not a member of the LinkedIn Cell Therapy Industry Group, check it out.


--Lee

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/EOlUEgJGsTQ/cell-therapy-industry-group-welcomes.html

I'm pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today. 


The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration.  The group's focus is on the activities of companies in and serving the space.


The group began in July 2008. It took 2.5 years to reach the first 1000 members, 9 mos to reach 2,0000, 6 months to reach 3,000, and 6 months to meet today's 4,000 member mark. 


As is typical, there is a very high percentage of passive participants but the group benefits from an avid group of participants who post, share, exchange, and debate on a range of topics ranging from regulatory, clinical, commercial, scientific, manufacturing, financial, and other topics of interest to the group.


As the group has grown I've noted two trends pertaining to the composition of the membership:  (a) having tapped out the c-level suite, growth is increasingly coming from down the hierarchy of the corporate food chain and including those in the operational trenches, and (b) a much higher ratio of new members of late is from outside the US, presumably as LinkedIn increasingly penetrates OUS markets.


We strive hard to maintain the quality of the participation by screening each applicant, deleting off-topic posts, moving promotional posts to the "promotions" tab" and encouraging a balance of news-sharing with useful discussion threads.


I'm proud to say the group has become a vibrant and valuable part of the sector due to the hard work and contributions of all involved.    


As these kind of virtual networks become exponentially larger and provide different value than the professional societies representing the sector, I will be fascinated to watch if and how this affects how sectors like our interact and how this will impact the traditional value proposition of member-based professional societies.


If you are not a member of the LinkedIn Cell Therapy Industry Group, check it out.


--Lee

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/EOlUEgJGsTQ/cell-therapy-industry-group-welcomes.html

PRP Vs Stem Cell Therapy
PRP Therapy Vs Stem Cell TherapyFrom:MiamiFootSurgeryViews:5 0ratingsTime:01:23More inHowto Style

More here:
PRP Vs Stem Cell Therapy - Video

PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:7 0ratingsTime:08:01More inPeople Blogs

See the rest here:
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 - Video

PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (English Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:8 0ratingsTime:09:00More inPeople Blogs

Read the rest here:
PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 - Video

Govt. Appoints Task Force To Explore Stem Cell Research
Minister of Health Hon. Dr. Perry Gomez announced that the government has appointed a 10 member task force, charged with making recommendations to the government to explore stem cell therapy in The Bahamas.From:ZNSNetworkViews:27 0ratingsTime:03:27More inNews Politics

See the rest here:
Govt. Appoints Task Force To Explore Stem Cell Research - Video

123Triad : wwmsbiologicscom
123Triad is proud to design website for http://www.wwmsbiologics.com WorldWide Medical Services Inc. is a company that for more than 10 years is dedicated to utilizing the most innovative technologies to provide its clients with the highest quality services. Worldwide Medical Services specializes in the Intra-operative treatment of surgical patients. One of their most exciting new products is platelet gel and adult stem cell therapy services which can be provided in a hospital or office setting. their Autotransfusion service is available 24/7 on a scheduled or emergency basis.From:123triadcoViews:1 0ratingsTime:00:36More inScience Technology

Continue reading here:
123Triad : wwmsbiologicscom - Video

CombiCult® Workflow
A overview on how Plasticell (www.plasticell.co.uk) uses combinatorial cell culture (CombiCult®) to discover optimised stem cell differentiation protocols in record time, at a fraction of the cost of the status quo while reducing project return risk. CombiCult® is used by our customers in a range of applications in regenerative medicine, cell therapy and research and development.From:PlasticellLimitedViews:1 0ratingsTime:06:40More inScience Technology

See the rest here:
CombiCult® Workflow - Video

blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy
http://www.cordbloodrecommendation.com Umbilical cord blood is stored immediately after delivery, when the cord is cut. Diseases that are genetically based would most likely be an allogenic transplant. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. Scientists have found that umbilical blood can actually help to treat many types of medical issues. To make a long story short, the Adult Stem Cells did the trick. This would be a significant event, which would save thousands of lives of those waiting for an organ. Why would someone opt for cord blood preservation? Well, research is continually being conducted and cells extracted from this blood has already been used to treat and cure injuries and diseases. Cord Blood Banking facilities are places where you can bank your child #39;s cord blood and use it later on in life to cure life-threatening diseases. The National Cord Blood Program staff at the New York Blood Center performs cord blood collection from the expelled placenta. Because of this amazing capacity of blood cells, they have been, still are and will continue to be used more and more to save lives and cure a number of diseases. ""Umbilical cord blood contains blood-forming cells that can be used to treat life-threatening diseases and conditions. Stem cells, researchers discovered, could cure many diseases such as leukemia and ...From:hotelesenMelgarViews:0 0ratingsTime:01:18More inScience Technology

Read the rest here:
blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy - Video

Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are cells which have the potential to develop into virtually any cells of the body. The characteristics of stem cells render them great possibility in treating illness as well as health rejuvenation. Stem cells can repair and renew damaged cells as well as replace the dead ones so that a damaged organ or tissue can be healed to its healthy state. Visit Stem Cell Malaysia at http:/stemcellmalaysia.com/ for more information on stem cells and stem cell therapy.From:stemcells2012Views:1 1ratingsTime:06:33More inHowto Style

More:
Stem Cells | Stem Cell Malaysia - Video

Stem Cell Research and TNG
How close is Science to providing visors for the blind? Or what about curing blindness? Have you watched the episode "The Masterpiece Society" from season 5 of TNG? Cause I have a couple of philosophical things to say about that! An article about STEM CELL therapy in regards to vision impairment: abcnews.go.com Interview with TrekMate: http://www.trekmate.org.uk ***I feel like the Star Trek community is a lot bigger then what YouTube has to offer, so I #39;ve started uploading my own videos. A lot of you will find this painfully dorky -and it is- which is why constructive criticism is welcomed. For anyone who does like my posts, thank you! It would be nice to gather a little Trekkie community :)***From:ThatTrekkieGirlViews:6 1ratingsTime:06:51More inPeople Blogs

Go here to read the rest:
Stem Cell Research and TNG - Video

Thelma before Stem Cell Therapy
From:krazykp12Views:2 0ratingsTime:01:33More inPeople Blogs

Read this article:
Thelma before Stem Cell Therapy - Video

NEW YORK (AP) Shares of biotechnology company Pluristem Therapeutics Inc. bounced back Friday after the company responded to a report that a patient treated with its PLX stem cell therapy had died.

THE SPARK: Bloomberg BusinessWeek reported Thursday that Pluristem did not disclose the death of a young patient who had been treated with its placental cell therapy before a $32 million public stock sale in September. Shares of Pluristem fell 23 percent Thursday.

The Israeli company said Thursday evening that parts of the article were inaccurate or misleading. It said the patient, a Romanian girl whose name has not been disclosed, was "in imminent danger of death" at the time she was treated with the stem cells. She was not part of an organized clinical trial and was treated on a compassionate basis because no therapy options remained.

Pluristem said the patient lived for six months after her treatment. She returned to Romania four months before she died and the company was not monitoring her health. Pluristem said it was not aware of her death at the time it sold the additional stock. Bloomberg said the patient died Sept. 12, the day the stock sale was announced. The sale closed a week later.

"The formal report relating to the death clearly stated that there was no connection between the PLX cell treatment and the death of the patient," Pluristem said in a press release.

THE BIG PICTURE: Pluristem said that three patients have been treated with PLX on a compassionate basis including the Romanian girl and two have died. The company said it believes the patients lived longer than expected following treatment, which demonstrates that PLX therapy can be effective. The company is studying the stem cells as a treatment for peripheral artery disease, nerve pain, and other conditions.

THE STOCK: Shares of Pluristem rose 39 cents, or 13.7 percent, to $3.24 on Friday. The stock reached an annual high of $5 per share in August, and including Friday's gains, the shares are down 29 percent since the company announced the stock offering.

Go here to read the rest:
Pluristem shares bounce back after Thursday plunge

Washington, November 7 (ANI): Stem cell therapy improves heart function in patients who had previous heart attacks, according to researchers from the University of Louisville and Brigham and Women's Hospital.

In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.

They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat.

No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack.

"The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL.

"The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study," he stated.

The trial - called SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy - was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower; the normal LVEF is 50 percent or higher.

The investigators harvested the CSCs, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from 33 patients during coronary artery bypass surgery. The stem cells were purified and processed in Anversa's lab in Boston so that they could multiply. Once an adequate number of stem cells was produced - about one million for each patient - Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the heart attack.

The researchers reported that in the 20 patients receiving CSCs, LVEF increased from 29 percent to 36 percent at four months following infusion. None of the 13 control patients in the trial received CSCs and this group showed, on average, no improvement.

The beneficial effect of the CSCs persisted and became progressively greater at the one- and two-year mark following infusion. At the one-year mark following infusion, LVEF increased by 8.1 percent, and at the two-year mark, by 12.9 percent.

View original post here:
Stem cell therapy improves heart function 2 years after heart attack

Published on 10 November 2012 Hits: 52 Written by Jovee Marie N. Dela Cruz

The Department of Health (DOH) on Friday said that it has become necessary to issue regulations for stem cell therapy in the country. Health Secretary Enrique Ona said that guidelines for clinics offering stem cell therapy will be released immediately by the DOH and the Food and Drug Administration.

We will issue guidelines because here in the country we dont know where the stem cell offered by clinics come from, he said.

According to the DOH, stem cell therapy belongs to the category of advanced cell therapy, which includes biologics and blood. Many countries apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy.

In many countries, stem cell is considered an investigational intervention, Ona said.

The DOH said that stem cell research employs both autologous (from same person) or allogenic (from another organism like an animal or another human cell or tissue sample) method.

Ona said that because there are many steps in the preparation of this lab and invasive procedure, there is a need to have a regulatory framework to protect Filipino citizens.

Continued here:
DOH to regulate stem cell therapy in PH

April Flowers for redOrbit.com Your Universe Online

Conflicting studies were highlighted at this years American Heart Association Scientific Sessions meeting concerning stem cell therapy for heart attack patients.

The first study, from the University of Louisville and Brigham and Womens Hospital, reported holy grail results for a Phase I clinical trial: marked sustained improvement in all patients with zero adverse effects.

Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Womens Hospital presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks in a Late-Breaking Clinical Trial session.

The researchers report that all patients receiving the stem cell therapy showed improved heart function after two years, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF). LVEF is a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. They saw no adverse effects from the therapy. In fact, nine patients showed evidence of myocardial regeneration new tissue replacing formerly dead tissue killed by heart attack in MRI scans.

The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient, said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL. The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study.

In all patients, cells with high regenerative reserve were obtained and employed therapeutically, said Anversa, professor of Anesthesia and Medicine at Brigham and Womens Hospital and Harvard Medical School. Our efforts to carefully characterize the phenotype and growth properties of the cardiac stem cells may have contributed to these initial positive results.

The Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, or SCIPIO, trial was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower. A normal LVEF reading is 50 percent or higher.

The CSCs, referred to as c-kit positive cells because they express the c-kit protein on their surface, were harvested from 33 patients during coronary artery bypass surgery. The stem cells were then purified and processed so that they could multiply, and once an adequate number was produced about one million for each patient they were reintroduced into the region of the patients heart that suffered scarring during the heart attack.

At four months after infusion, the researchers report that LVEF increased from 29 percent to 36 percent for 200 patients. On average, the 13 control patients who did not receive a CSC infusion showed any improvement.

Visit link:
Studies On Stem Cell Therapy After Heart Attack Show Mixed Results

UPDATE on Stem Cell Therapy

7 November 2012

The Department of Health (DOH) saw the necessity to cover regulations for Stem Cell therapy. Stem Cell therapy belongs to the category of Advanced Cell therapy which includes biologics and blood. Many countries around the world apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy. In many countries, Stem Cell is considered an investigational intervention.

Stem Cell research employs both autologous (from same person) or allogenic (from another organism like animal or another human cell or tissue sample) method. Because there are many steps in the preparation of this lab and invasive procedure, there is therefore need to have a regulatory framework to protect Filipino citizens.

Important questions were asked: is there proof of concept in animal trials where stem cell can then be applied in humans? Is there a way to ensure quality and purity of the raw materials? How safe is the procedure? How many did not benefit from the procedure? If this were investigational procedure, how will human subjects be protected?

Sec. Enrique Ona convened a consultative working task force to provide recommendations on how to proceed in the early part of the year in response to queries and mushrooming of centers here and overseas. This led to the creation of a regulatory task force to oversee the appropriate steps that will ensure quality, efficacy and safety documentation of this intervention.

Read more from the original source:
UPDATE on Stem Cell Therapy 7 November 2012

cryo cell | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health
http://www.cordbloodrecommendation.com They were first used to regenerate healthy blood and immune cells for cancer patients. The treatment that has to be provided for leukemia should be such, that it would increase the amount of White Blood cells in the blood stream. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. This procedure can likewise diagnose disorders like malformations of fetus, fetal infection such as toxoplasmosis or rubella, fetal platelet count inside mum, fetal anaemia, and isoimmunisation to name a few. To make a long story short, the Adult Stem Cells did the trick. If the amount is less, the collected cord blood is used for scientific researches. Within an hour of receiving the stem cell treatment, she was able to turn her head and partially lift her arms. If there is any complication during delivery, the entire idea is abandoned. It is always wise to preserve this waste blood of the baby which is otherwise thrown away. The placenta and umbilical cord is often discarded along with the hospital #39;s medical waste. It is a simple and safe procedure for the mother and the baby, and is done by the doctor or the nurse. These cells have a unique capability of ""adjusting in any environment inside the body"". This is still new methodology but holds great promise for the future of regenerative therapies. This enables stem ...From:myc0kyViews:0 0ratingsTime:01:18More inScience Technology

Read the original post:
cryo cell | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health - Video